Non Hormonal Contraceptives Market

Non Hormonal Contraceptives Market Overview

The non hormonal contraceptives market is estimated to be worth $1.8 billion in 2021 and is expected to grow at CAGR of 22% during the forecast period.

According to the World Health Organization (WHO), sexual and reproductive health-related conditions represent around one third of all clinical conditions prevalent among women between the ages of 15 and 44 years. The human female reproductive system is complex and governed primarily by two hormones, estrogen and progesterone. Any imbalance in the levels of these hormones materializes in the form of a disease, and / or mood related disorders; in fact, women are more prone to experiencing various forms of anxiety, depression and certain physical symptoms that cannot yet be explained medically, as compared to men. Since hormones are responsible for almost all of the concerns associated with reproductive health, a number of hormone regulating interventions have been developed, and are available, for the treatment / prevention of the clinical conditions that are unique to women.

This form of therapy has been proven to be both viable and effective, and have been in use since the 1960s. Such therapies gained better traction as mainstream healthcare solutions after clinical trials were conducted, proving their efficacy, in the late 1990s. Despite the vast success of using hormones as therapeutics, later studies reflected a positive correlation between the use of such interventions and several unwanted side effects, including the risk of developing hormone dependent cancers.

In recent years, the development and introduction of non hormonal contraceptives has revolutionized women’s healthcare. Brisdelle® was the first of such non hormonal contraceptives, approved in 2013 for the management of hot flashes in menopausal women. Till date, 21 non hormonal contraceptives (recent examples include Oriahnn™, Phexxi™ and Esmya®) have been approved. Further, several such non hormonal birth control drug candidates are under evaluation across different stages of product development. The inherent advantages of non hormonal birth control therapies, such as better safety profile, ability to maintain hormonal balance and relatively short treatment courses, over their hormonal counterparts have been demonstrated both in clinical trials and post product approval studies.

As a result, such non hormonal contraceptives are currently preferred over hormone-based therapies, and the non hormonal birth control therapy pipeline is expected to continue to steadily expand over the coming years.It is worth highlighting that significant partnership activity has been observed in this market, with several stakeholders entering into strategic collaborations to support the ongoing product development and commercialization initiatives of such products. In the foreseen future, promising results from the ongoing clinical research initiatives are likely to bring in more investments to support product development activity in this upcoming market segment. Therefore, we are led to anticipate significant market growth in this domain during the forecast period.

Recent Developments in Non Hormonal Contraceptives Market:

Several recent developments have taken place in the field of non hormonal contraceptives market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

• In May 2026, Daré Bioscience reported positive interim safety and efficacy data from its Phase 3 trial of Ovaprene, a monthly hormone-free intravaginal contraceptive.
• In February 2026, NEXT Life Sciences progressed its non-hormonal male contraceptive candidates into Phase II trials, including NLS-133, an oral pill offering up to 24-hour contraception. The company also advanced its Plan A device following successful early feasibility studies, signaling growing momentum in non-hormonal contraceptive innovation for men.
• In February 2026, Teva Pharmaceuticals won the first US jury trial related to injury claims involving the Paragard copper intrauterine device, a non-hormonal contraceptive.

Scope of the Report

The “Non Hormonal Contraceptives Market for Women’s Health: Industry Trends and Global Forecasts, till 2030” market report features an extensive study of the current market landscape, market size, market share, market forecast, market outlook and future opportunities of the non hormonal contraceptives market, primarily focusing on prescription drugs. The market research report also includes an elaborate discussion on the future potential of this evolving market.

Amongst other elements, the market research report features:

• A detailed review of the overall market landscape of non-hormonal therapies, including information on their current phase of development (marketed, clinical, preclinical and discovery), type of molecule (biologic and small molecule),target indication (bacterial vaginosis, contraception, endometriosis, postmenopausal osteoporosis, uterine fibroids, vaginitis and others), purpose of therapy (treatment of disease and management of symptoms), target women population (adult, postmenarchal and premenopausal female, postmenopausal female), mechanism of action (antagonists, agonists, inhibitors and modulators), route of administration (intramuscular, intravaginal, intravenous, oral, subcutaneous, topical, transdermal and others) and special drug designation(s)awarded (if any).
• A detailed review of the players engaged in the development of non-hormonal therapies, along with information on their year of establishment, company size, location of headquarters and regional landscape.
• An elaborate discussion on the various commercialization strategies that can be adopted by drug developers engaged in non hormonal contraceptives market, across different stages of therapy development, including prior to drug launch, at / during drug launch and post-marketing of the drug.
• Detailed profiles of phase III non-hormonal therapies. Each drug profile features a brief overview of the therapy, along with information on their current development status, route of administration, primary target indication, dosage, mechanism of action, clinical trials, clinical trial results, collaborations and special drug designation(s) received(if any).
• A detailed geographical clinical trial analysis of completed and ongoing studies of non-hormonal therapies, based on several relevant parameters, such as trial registration year, trial status, trial phase, target indication, geography, type of sponsor, prominent treatment sites and enrolled patient population.
• An analysis of the various partnerships that have been inked by stakeholders engaged in the development of non-hormonal therapies, during the period pre 2013-2020, including research agreements, research and development agreements, contract manufacturing agreements, licensing agreements and other relevant types of deals. It further features a detailed analysis of the investments made, including award / grant, seed financing, venture capital financing, debt financing and others, in companies engaged in non hormonal birth control market.

The key objective of non hormonal contraceptives market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for non hormonal contraceptives market during the forecast period. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the evolution of the market for the forecast period 2021-2030.

The market report also features the likely distribution of the current and forecasted opportunity across [A] target indication (bacterial vaginosis, contraception, endometriosis, postmenopausal osteoporosis, uterine fibroids, vaginitis and others), [B] type of molecule (biologic and small molecule), [C] route of administration (intramuscular, intravaginal, intravenous, oral, subcutaneous biologics, topical, transdermal and others), [D] key geographical regions (North America, Europe and Asia-Pacific). In addition, the chapter presents indication specific value creation analysis. In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.